Defense Funding, page-4

The article provides some brilliant insights into current thinking and strategic planning by stakeholder groups.

Including Rett Syndrome into the DoD's 2016 Appropriations Bill appears to reveal the view by 'officials' that the successful application of Trofinetide in Rett will directly translate into TBI. We all know, however, the point being made about the common underlying pathology in neurodegenerative and neurodevelopmental disorders.

More importantly is the strategic thinking behind the move. The article points out that Rett - through its orphan status - can make medications more quickly available than if developed solely for the purpose of treating TBI.

From the thread the Clock is Ticking posted back in December 2014;
Breakthrough therapy designation is a fast drug mechanism which is good news for the Rett community. It's also potentially good news for people suffering from all types of neurodevelopmental and neurodegenerative conditions. The simple explanation is the prevalent prescribing for off-label drug use. According to one source, more than one in five outpatient prescriptions written in the US are for off-label therapies. The FDA regulates drug approval but doctors prescribe drug use.

It would appear that the Army is intently watching the clock and has found a way to fast forward the time for the urgent approval for Trofinetide to treat CNS conditions.